At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 13 enrolled
Drug / intervention
CC-4047drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2, Open-Label, Single-Arm, Pilot Study of Safety and Efficacy of CC-4047 (Pomalidomide) in Patients With Advanced Chronic Graft-Versus-Host Disease Developing After Allogeneic Hematological Stem Cell Transplantation
In Brief
A Phase 2 clinical trial evaluating CC-4047 for Graft vs Host Disease. Completed, enrolled 13 participants across 1 site.
Detailed Summary
This study will test the safety and effectiveness CC-4047 (pomalidomide) in patients with advanced, steroid refractory graft-versus-host disease.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGraft vs Host Disease
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedOct 2008
Enrollment StartFeb 2009
Primary CompletionOct 2010
Study CompletionOct 2011
TodayJul 2026
First PostedOct 10, 2008
Enrollment StartFeb 1, 2009
Primary CompletionOct 1, 2010
Study CompletionOct 1, 2011
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 17.7 years ago
Interventions
CC-4047drug